Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-021-03324-6 http://scihub22266oqcxt.onion/10.1038/s41586-021-03324-6 33567448!8503938!33567448     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2021 ; 592 (7855): 616-622 Nephropedia Template TP {{tp|p=33567448|t=2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants |pdf=|usr=}}{{33567448}} gab.com Text mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=33567448 #FOAvip Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-2(1-4). Eight weeks after the second injection of vaccine, volunteers showed high levels of IgM and IgG anti-SARS-CoV-2 spike protein (S) and receptor-binding-domain (RBD) binding titre. Moreover, the plasma neutralizing activity and relative numbers of RBD-specific memory B cells of vaccinated volunteers were equivalent to those of individuals who had recovered from natural infection(5,6). However, activity against SARS-CoV-2 variants that encode E484K-, N501Y- or K417N/E484K/N501-mutant S was reduced by a small-but significant-margin. The monoclonal antibodies elicited by the vaccines potently neutralize SARS-CoV-2, and target a number of different RBD epitopes in common with monoclonal antibodies isolated from infected donors(5-8). However, neutralization by 14 of the 17 most-potent monoclonal antibodies that we tested was reduced or abolished by the K417N, E484K or N501Y mutation. Notably, these mutations were selected when we cultured recombinant vesicular stomatitis virus expressing SARS-CoV-2 S in the presence of the monoclonal antibodies elicited by the vaccines. Together, these results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid a potential loss of clinical efficacy. Twit Text FOAVip mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=33567448 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33567448 #FOAvip English Wikipedia <ref>{{Cite pmid|33567448}}</ref> mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants #MMPMID33567448 Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC Nature 2021[Apr]; 592 (7855): 616-622 PMID33567448show ga Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-2(1-4). Eight weeks after the second injection of vaccine, volunteers showed high levels of IgM and IgG anti-SARS-CoV-2 spike protein (S) and receptor-binding-domain (RBD) binding titre. Moreover, the plasma neutralizing activity and relative numbers of RBD-specific memory B cells of vaccinated volunteers were equivalent to those of individuals who had recovered from natural infection(5,6). However, activity against SARS-CoV-2 variants that encode E484K-, N501Y- or K417N/E484K/N501-mutant S was reduced by a small-but significant-margin. The monoclonal antibodies elicited by the vaccines potently neutralize SARS-CoV-2, and target a number of different RBD epitopes in common with monoclonal antibodies isolated from infected donors(5-8). However, neutralization by 14 of the 17 most-potent monoclonal antibodies that we tested was reduced or abolished by the K417N, E484K or N501Y mutation. Notably, these mutations were selected when we cultured recombinant vesicular stomatitis virus expressing SARS-CoV-2 S in the presence of the monoclonal antibodies elicited by the vaccines. Together, these results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid a potential loss of clinical efficacy. |2019-nCoV Vaccine mRNA-1273[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Monoclonal/blood/immunology[MESH] |Antibodies, Neutralizing/blood/immunology[MESH] |Antibodies, Viral/*blood/immunology[MESH] |B-Lymphocytes/immunology[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/genetics/*immunology[MESH] |COVID-19/*immunology/*virology[MESH] |Cryoelectron Microscopy[MESH] |Epitopes, B-Lymphocyte/chemistry/immunology/ultrastructure[MESH] |Female[MESH] |Humans[MESH] |Immunization, Secondary[MESH] |Immunoglobulin G/blood/immunology[MESH] |Immunoglobulin M/blood/immunology[MESH] |Immunologic Memory/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Models, Molecular[MESH] |Mutation[MESH] |Neutralization Tests[MESH] |SARS-CoV-2/genetics/*immunology[MESH] |Spike Glycoprotein, Coronavirus/chemistry/*genetics/immunology[MESH] |Vaccines, Synthetic/genetics/*immunology[MESH]mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variant(epmc).pdf DeepDyve Pubget Overpricing